
Takeda Pharmaceutical Co Ltd 4502.T:
TAKEDA ANNOUNCES U.S. FDA APPROVAL OF GAMMAGARD LIQUID ERC, THE ONLY READY-TO-USE LIQUID IMMUNOGLOBULIN THERAPY WITH LOW IMMUNOGLOBULIN A (IGA) CONTENT1
TAKEDA PHARMACEUTICAL CO LTD - TO DISCONTINUE FIRST-GENERATION LOW-IGA PRODUCT
TAKEDA PHARMACEUTICAL CO LTD - GAMMAGARD LIQUID ERC U.S. COMMERCIALIZATION PROJECTED FOR 2026
TAKEDA PHARMACEUTICAL CO LTD - GAMMAGARD S/D MANUFACTURING TO BE DISCONTINUED END OF DECEMBER 2027
TAKEDA PHARMACEUTICAL CO LTD - TO MAINTAIN GAMMAGARD S/D INVENTORY UNTIL DEPLETED OR EXPIRED